Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.
Explore this paper's citation graph
Summary
CTX-II decreased with risedronate in patients with knee OA and levels reached after 6 months were associated with radiological progression at 24 months, and monitoring a marker of cartilage degradation 6 months after initiating treatment may be instructive in identifying patients with low progression.
- Type
- article
- Published
- 2008-06-01
- Cited by
- 92
- References
- 41
- Access
- Open access
- OpenAlex
- https://openalex.org/W1965427698
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5920653
Keywords
Medicine, Osteoarthritis, Odds ratio, Internal medicine, N-terminal telopeptide
References
- Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]
- X-ray technologists' reproducibility from automated measurements of the medial tibiofemoral joint space width in knee osteoarthritis for a multicenter, multinational clinical trial.
- Bone Marrow Edema and Its Relation to Progression of Knee Osteoarthritis
- Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
- Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy.
- Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
- Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip.
- Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.
- Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study.
- The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis.
- Collagen type II C-telopeptide fragments as an index of cartilage degradation.
- A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.
- Use of biochemical markers to study and follow patients with osteoarthritis
- Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis.
- Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years.
- The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
- Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis.
- Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association.
- Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study.
- Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate.
Cited by
- Effect of exercise and osteochondral injury on synovial fluid and serum concentrations of carboxy-terminal telopeptide fragments of type II collagen in racehorses.
- Molecular serum and urine marker repertoire supporting clinical research on joint diseases.
- Osteoarthritis and osteoporosis: correlations between two clinical entities.
- “Flare” and disease worsening in rheumatoid arthritis: Time for a definition
- Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain
- Investigational drugs for the treatment of osteoarthritis
- Biomarkers in the development of novel disease-modifying therapies for osteoarthritis.
- Biochemical Markers of Joint Tissue Turnover
- In vivo structural analysis of subchondral trabecular bone in osteoarthritis of the hip using multi-detector row CT.
- Urinary CTX-II Concentrations are Elevated and Associated with Knee Pain and Function in Subjects with ACL Reconstruction
- Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria.
- Animal models in OA: a means to explore bone
- Clinical, radiographic, molecular and MRI-based predictors of cartilage loss in knee osteoarthritis
- First Qualification Study of Serum Biomarkers as Indicators of Total Body Burden of Osteoarthritis
- Bone-cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies.
- Osteochondral alterations in osteoarthritis.
- In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
- Bone marrow lesions: a universal bone response to injury?
- The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?
- Subchondral bone as a key target for osteoarthritis treatment.
Related papers
- Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.
- [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
- An Atlas of Osteoarthritis
- Individuals with accelerated knee osteoarthritis have greater pain and functional impairments than individuals with common knee osteoarthritis: Data from the osteoarthritis
- Plasma levels of carboxy terminal propeptide of type I procollagen and pyridinoline cross-linked telopeptide of type I collagen in healthy school children
- Conditioned placebo analgesia persists when subjects know they are receiving a placebo
- Relationship between the markers of cartilage collagens and osteoarthritis
- Correlation of cartilage metabolic markers & antioxidants with the severity of knee osteoarthritis
- Hematic levels of type I collagen C-telopeptide in erosive versus nonerosive osteoarthritis of the hands.